Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>We have screened for APAC (ex-China) healthcare companies using their respective Smart Score, a compound score for a company indicating its overall outlook based on key factors.</li>
<li>Smart Score screens the stock based on five major components including value, dividends, growth, resilience, and momentum. It also provides a cumulative score, which puts equal weightage on each parameter.  </li>
<li>Parameters used to screen the stocks: market cap≥ $800M and smart score≥ 3.5. We have seen stocks having high smart score has strong growth prospects and qualify for investment proposition.</li>
</ul>


We have screened for APAC (ex-China) healthcare companies using their respective Smart Score, a compound score for a company indicating its overall outlook based on key factors.
Smart Score screens the stock based on five major components including value, dividends, growth, resilience, and momentum. It also provides a cumulative score, which puts equal weightage on each parameter.  
Parameters used to screen the stocks: market cap≥ $800M and smart score≥ 3.5. We have seen stocks having high smart score has strong growth prospects and qualify for investment proposition.


Top APAC (Ex-China) Investment Worthy Healthcare Companies Using Smartkarma’s Smart Score Screener

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>Natco's business model is centered on high-risk, high-reward Para IV/First-to-File (FTF) generic drug launches in the US, leading to a lumpy but potentially highly profitable earnings profile.</li>
 <li>The company faces a significant revenue and profit decline post-FY26 due to the loss of exclusivity for its blockbuster generic, Revlimid, which has been a primary growth driver.</li>
 <li>Future growth hinges on the successful execution of its R&amp;D pipeline, strategic M&amp;A to diversify revenue, and the expansion of its Crop Health Sciences division, which is being demerged into a separate entity.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Natco's business model is centered on high-risk, high-reward Para IV/First-to-File (FTF) generic drug launches in the US, leading to a lumpy but potentially highly profitable earnings profile.
  The company faces a significant revenue and profit decline post-FY26 due to the loss of exclusivity for its blockbuster generic, Revlimid, which has been a primary growth driver.
  Future growth hinges on the successful execution of its R&amp;D pipeline, strategic M&amp;A to diversify revenue, and the expansion of its Crop Health Sciences division, which is being demerged into a separate entity.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Natco Pharma (NTCPH IN) - Aug 2026

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

<ul>
<li>On 20th March 2026, the critical patent for Semaglutide expires in India, decisively ending the innovator's legal monopoly and enabling highly affordable generic versions. </li>
<li>This triggers a massive 70% retail price drop in India, exponentially expanding affordable access to millions suffering from prevalent obesity and diabetes.</li>
<li>Vertically integrated formulators like Sun Pharma and specialized API manufacturers like Divis Laboratories capture maximum alpha through scaled volumes and zero customer acquisition costs.</li>
</ul>


On 20th March 2026, the critical patent for Semaglutide expires in India, decisively ending the innovator's legal monopoly and enabling highly affordable generic versions. 
This triggers a massive 70% retail price drop in India, exponentially expanding affordable access to millions suffering from prevalent obesity and diabetes.
Vertically integrated formulators like Sun Pharma and specialized API manufacturers like Divis Laboratories capture maximum alpha through scaled volumes and zero customer acquisition costs.


The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

<ul>
<li>CSPC Pharmaceutical’s SYS6010 met primary endpoint in Phase 3 study as a monotherapy for NSCLC. Akeso’s ivonescimab demonstrates significant overall survival in Phase 3 trial for advanced biliary tract cancer.</li>
<li>Takeda Pharma secured FDA approval for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera. Astellas Pharma initiates global Phase 3 study evaluating ASP2138 for gastric cancers.</li>
<li>Hanmi Pharm outlicenses obesity drug candidate HM1732 to Genentech for a total deal value of $2.3B. SK Biopharmaceuticals entered an agreement to in-license opakalim, an investigational antiseizure medication, from Biohaven.</li>
</ul>


CSPC Pharmaceutical’s SYS6010 met primary endpoint in Phase 3 study as a monotherapy for NSCLC. Akeso’s ivonescimab demonstrates significant overall survival in Phase 3 trial for advanced biliary tract cancer.
Takeda Pharma secured FDA approval for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera. Astellas Pharma initiates global Phase 3 study evaluating ASP2138 for gastric cancers.
Hanmi Pharm outlicenses obesity drug candidate HM1732 to Genentech for a total deal value of $2.3B. SK Biopharmaceuticals entered an agreement to in-license opakalim, an investigational antiseizure medication, from Biohaven.


APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

<ul>
<li>India recorded an estimated 1.56 million new cancer cases and 0.90 million deaths in 2024. The long-duration demand curve points toward materially higher case volumes by 2040–50.</li>
<li>The listed opportunity is concentrated in oncology capacity, radiotherapy, surgery, diagnostics and accessible drugs. These are scalable revenue pools today, not distant optionality.</li>
<li>HCG Offers the highest cancer purity; Max and Apollo combine oncology with network strength; Medanta adds capacity optionality. Biocon, Dr. Reddy’s and Metropolis are indirect enablers.</li>
</ul>


India recorded an estimated 1.56 million new cancer cases and 0.90 million deaths in 2024. The long-duration demand curve points toward materially higher case volumes by 2040–50.
The listed opportunity is concentrated in oncology capacity, radiotherapy, surgery, diagnostics and accessible drugs. These are scalable revenue pools today, not distant optionality.
HCG Offers the highest cancer purity; Max and Apollo combine oncology with network strength; Medanta adds capacity optionality. Biocon, Dr. Reddy’s and Metropolis are indirect enablers.


India’s Cancer Care Opportunity: Listed Proxies for a 1.6 Million-Case Market

India

NATCO Pharma is a research and development-driven pharmaceutical company focused on complex generics, niche products, and active pharmaceutical ingredients (APIs). It specializes in various therapeutic areas including oncology, cardiology, and diabetology, and also has a Crop Health Sciences division for agrochemical products. The company is headquartered in Hyderabad, India, and was founded in 1981.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

NATCO Pharma (NTCPH IN)

Top APAC (Ex-China) Investment Worthy Healthcare Companies Using Smartkarma’s Smart Score Screener

We have screened APAC (ex-China) healthcare companies with market cap≥$800M using Smartkarma’s Smart Score and picked up 2 investable ideas by...

Tina Banerjee

Primer: Natco Pharma (NTCPH IN) - Aug 2026

Natco's business model is centered on high-risk, high-reward Para IV/First-to-File (FTF) generic drug launches in the US, leading to a lumpy but...

αSK Primers

The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.

Nimish Maheshwari

APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...

Tina Banerjee

India’s Cancer Care Opportunity: Listed Proxies for a 1.6 Million-Case Market

India faces a growing cancer burden with 1.56 million new cases in 2024, highlighting the need for increased oncology capacity and accessible...

Nimish Maheshwari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Top APAC (Ex-China) Investment Worthy Healthcare Companies Using Smartkarma’s Smart Score Screener

We have screened APAC (ex-China) healthcare companies with market cap≥$800M using Smartkarma’s Smart Score and picked up 2 investable ideas by...

Tina Banerjee

Primer: Natco Pharma (NTCPH IN) - Aug 2026

Natco's business model is centered on high-risk, high-reward Para IV/First-to-File (FTF) generic drug launches in the US, leading to a lumpy but...

αSK Primers

The GLP-1 Super-Cycle: Deconstructing India’s 2026 Patent Cliff and Alpha Generators

​Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.

Nimish Maheshwari

APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...

Tina Banerjee

India’s Cancer Care Opportunity: Listed Proxies for a 1.6 Million-Case Market

​India faces a growing cancer burden with 1.56 million new cases in 2024, highlighting the need for increased oncology capacity and accessible...

Nimish Maheshwari

Semaglutide patent expiration in India leads to 70% price drop, increasing access to affordable generic versions for obesity and diabetes treatment.

India faces a growing cancer burden with 1.56 million new cases in 2024, highlighting the need for increased oncology capacity and accessible...